Fiera Capital Corp lowered its stake in shares of Catalent Inc (NYSE:CTLT) by 7.7% in the second quarter, HoldingsChannel.com reports. The firm owned 130,335 shares of the company’s stock after selling 10,946 shares during the quarter. Fiera Capital Corp’s holdings in Catalent were worth $5,459,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors also recently added to or reduced their stakes in CTLT. Champlain Investment Partners LLC boosted its position in Catalent by 19.2% during the 1st quarter. Champlain Investment Partners LLC now owns 3,627,390 shares of the company’s stock valued at $148,941,000 after purchasing an additional 583,675 shares during the period. Wells Fargo & Company MN boosted its position in Catalent by 59.8% during the 1st quarter. Wells Fargo & Company MN now owns 1,146,493 shares of the company’s stock valued at $47,074,000 after purchasing an additional 429,061 shares during the period. Prudential Financial Inc. boosted its position in Catalent by 48.0% during the 1st quarter. Prudential Financial Inc. now owns 1,041,568 shares of the company’s stock valued at $42,767,000 after purchasing an additional 337,828 shares during the period. GW&K Investment Management LLC boosted its position in Catalent by 16.1% during the 1st quarter. GW&K Investment Management LLC now owns 1,903,864 shares of the company’s stock valued at $78,173,000 after purchasing an additional 263,963 shares during the period. Finally, Impax Asset Management LLC boosted its position in Catalent by 152.3% during the 1st quarter. Impax Asset Management LLC now owns 433,796 shares of the company’s stock valued at $17,812,000 after purchasing an additional 261,851 shares during the period. Institutional investors and hedge funds own 99.61% of the company’s stock.
Shares of Catalent opened at $40.22 on Friday, MarketBeat reports. The company has a debt-to-equity ratio of 2.53, a quick ratio of 1.78 and a current ratio of 2.18. The firm has a market cap of $5.47 billion, a price-to-earnings ratio of 25.50, a price-to-earnings-growth ratio of 1.80 and a beta of 1.44. Catalent Inc has a 1-year low of $33.42 and a 1-year high of $47.87.
CTLT has been the subject of a number of analyst reports. Zacks Investment Research upgraded Catalent from a “hold” rating to a “buy” rating and set a $44.00 price objective for the company in a research report on Thursday, May 10th. ValuEngine lowered Catalent from a “buy” rating to a “hold” rating in a research report on Tuesday, June 5th. Six research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $46.00.
In other Catalent news, SVP Steven L. Fasman sold 2,252 shares of Catalent stock in a transaction on Wednesday, June 20th. The stock was sold at an average price of $41.78, for a total transaction of $94,088.56. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 1.70% of the stock is owned by insiders.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.